Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Combined MEK and PI3K/p110b inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features.

Marqués M, Tranchant R, Risa-Ebrí B, Suárez-Solís ML, Fernández LC, Carrillo-de-Santa-Pau E, Del Pozo N, Martínez de Villarreal J, Meiller C, Allory Y, Blum Y, Pirker C, Hegedus B, Barry ST, Carnero A, Berger W, Jean D, Real FX.

Cancer Res. 2020 Jan 7. pii: canres.1633.2019. doi: 10.1158/0008-5472.CAN-19-1633. [Epub ahead of print]

PMID:
31911549
2.

Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.

Vlacic G, Hoda MA, Klikovits T, Sinn K, Gschwandtner E, Mohorcic K, Schelch K, Pirker C, Peter-Vörösmarty B, Brankovic J, Dome B, Laszlo V, Cufer T, Rozman A, Klepetko W, Grasl-Kraupp B, Hegedus B, Berger W, Kern I, Grusch M.

Cells. 2019 Sep 16;8(9). pii: E1091. doi: 10.3390/cells8091091.

3.

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma.

Gabler L, Lötsch D, Kirchhofer D, van Schoonhoven S, Schmidt HM, Mayr L, Pirker C, Neumayer K, Dinhof C, Kastler L, Azizi AA, Dorfer C, Czech T, Haberler C, Peyrl A, Kumar R, Slavc I, Spiegl-Kreinecker S, Gojo J, Berger W.

Acta Neuropathol Commun. 2019 Aug 7;7(1):128. doi: 10.1186/s40478-019-0775-6.

4.

Subcellular Duplex DNA and G-Quadruplex Interaction Profiling of a Hexagonal PtII Metallacycle.

Domarco O, Kieler C, Pirker C, Dinhof C, Englinger B, Reisecker JM, Timelthaler G, García MD, Peinador C, Keppler BK, Berger W, Terenzi A.

Angew Chem Int Ed Engl. 2019 Jun 11;58(24):8007-8012. doi: 10.1002/anie.201900934. Epub 2019 May 8.

5.

Metal Drugs and the Anticancer Immune Response.

Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, Berger W.

Chem Rev. 2019 Jan 23;119(2):1519-1624. doi: 10.1021/acs.chemrev.8b00396. Epub 2018 Nov 29.

PMID:
30489072
6.

The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition.

Hager S, Korbula K, Bielec B, Grusch M, Pirker C, Schosserer M, Liendl L, Lang M, Grillari J, Nowikovsky K, Pape VFS, Mohr T, Szakács G, Keppler BK, Berger W, Kowol CR, Heffeter P.

Cell Death Dis. 2018 Oct 15;9(11):1052. doi: 10.1038/s41419-018-1102-z.

7.

TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.

Spiegl-Kreinecker S, Lötsch D, Neumayer K, Kastler L, Gojo J, Pirker C, Pichler J, Weis S, Kumar R, Webersinke G, Gruber A, Berger W.

Neuro Oncol. 2018 Nov 12;20(12):1584-1593. doi: 10.1093/neuonc/noy104.

8.

Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins.

Heilos D, Röhrl C, Pirker C, Englinger B, Baier D, Mohr T, Schwaiger M, Iqbal SM, van Schoonhoven S, Klavins K, Eberhart T, Windberger U, Taibon J, Sturm S, Stuppner H, Koellensperger G, Dornetshuber-Fleiss R, Jäger W, Lemmens-Gruber R, Berger W.

Oncotarget. 2018 May 22;9(39):25661-25680. doi: 10.18632/oncotarget.25432. eCollection 2018 May 22.

9.

Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo.

Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirok A, Garay T, Stiglbauer A, Helbich TH, Gröger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B.

Clin Cancer Res. 2018 Aug 1;24(15):3729-3740. doi: 10.1158/1078-0432.CCR-17-1507. Epub 2018 May 3.

10.

Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Groza D, Gehrig S, Kudela P, Holcmann M, Pirker C, Dinhof C, Schueffl HH, Sramko M, Hoebart J, Alioglu F, Grusch M, Ogris M, Lubitz W, Keppler BK, Pashkunova-Martic I, Kowol CR, Sibilia M, Berger W, Heffeter P.

Oncoimmunology. 2018 Feb 16;7(5):e1424676. doi: 10.1080/2162402X.2018.1424676. eCollection 2018.

11.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.

Carcinogenesis. 2018 Apr 5;39(4):534-545. doi: 10.1093/carcin/bgy018.

PMID:
29635378
12.

Dynamics of CRISPR/Cas9-mediated genomic editing of the AXL locus in hepatocellular carcinoma cells.

Scharf I, Bierbaumer L, Huber H, Wittmann P, Haider C, Pirker C, Berger W, Mikulits W.

Oncol Lett. 2018 Feb;15(2):2441-2450. doi: 10.3892/ol.2017.7605. Epub 2017 Dec 13.

13.

CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model.

Mayr L, Pirker C, Lötsch D, Van Schoonhoven S, Windhager R, Englinger B, Berger W, Kubista B.

Oncotarget. 2017 Dec 9;8(69):114095-114108. doi: 10.18632/oncotarget.23125. eCollection 2017 Dec 26.

14.

FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.

Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, Peter-Vörösmarty B, Brankovic J, Lackner A, Leopoldi A, Meindl D, Pirker C, Hegedus B, Marian B, Holzmann K, Grasl-Kraupp B, Heffeter P, Berger W, Grusch M.

Oncotarget. 2017 Sep 23;8(50):87750-87762. doi: 10.18632/oncotarget.21184. eCollection 2017 Oct 20.

15.

Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.

Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G.

J Thorac Oncol. 2018 Feb;13(2):258-272. doi: 10.1016/j.jtho.2017.10.016. Epub 2017 Nov 4.

16.

Intrathoracic solitary fibrous tumor - an international multicenter study on clinical outcome and novel circulating biomarkers.

Ghanim B, Hess S, Bertoglio P, Celik A, Bas A, Oberndorfer F, Melfi F, Mussi A, Klepetko W, Pirker C, Berger W, Harmati I, Farkas A, Jan Ankersmit H, Dome B, Fillinger J, Aigner C, Hegedus B, Renyi-Vamos F, Lang G.

Sci Rep. 2017 Oct 2;7(1):12557. doi: 10.1038/s41598-017-12914-2.

17.

Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.

Englinger B, Kallus S, Senkiv J, Heilos D, Gabler L, van Schoonhoven S, Terenzi A, Moser P, Pirker C, Timelthaler G, Jäger W, Kowol CR, Heffeter P, Grusch M, Berger W.

J Exp Clin Cancer Res. 2017 Sep 7;36(1):122. doi: 10.1186/s13046-017-0592-3.

18.

Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis.

Schoenhacker-Alte B, Mohr T, Pirker C, Kryeziu K, Kuhn PS, Buck A, Hofmann T, Gerner C, Hermann G, Koellensperger G, Keppler BK, Berger W, Heffeter P.

Cancer Lett. 2017 Sep 28;404:79-88. doi: 10.1016/j.canlet.2017.07.009. Epub 2017 Jul 14.

PMID:
28716523
19.

[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice.

Traxl A, Beikbaghban T, Wanek T, Kryeziu K, Pirker C, Mairinger S, Stanek J, Filip T, Sauberer M, Kuntner C, Berger W, Langer O.

Nucl Med Biol. 2017 Sep;52:7-15. doi: 10.1016/j.nucmedbio.2017.05.007. Epub 2017 May 25.

PMID:
28575795
20.

Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.

Englinger B, Mair M, Miklos W, Pirker C, Mohr T, van Schoonhoven S, Lötsch D, Körner W, Ferk F, Knasmüller S, Heffeter P, Keppler BK, Grusch M, Berger W.

Br J Cancer. 2017 Feb 14;116(4):489-500. doi: 10.1038/bjc.2016.449. Epub 2017 Jan 17.

21.

Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.

Spitzwieser M, Pirker C, Koblmüller B, Pfeiler G, Hacker S, Berger W, Heffeter P, Cichna-Markl M.

Oncotarget. 2016 Nov 8;7(45):73347-73369. doi: 10.18632/oncotarget.12332.

22.

Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling.

Miklos W, Heffeter P, Pirker C, Hager S, Kowol CR, van Schoonhoven S, Stojanovic M, Keppler BK, Berger W.

Oncotarget. 2016 Dec 20;7(51):84556-84574. doi: 10.18632/oncotarget.11821.

23.

Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.

Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W.

Mol Cancer Ther. 2016 Oct;15(10):2357-2369. Epub 2016 Aug 10.

24.

Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.

Englinger B, Lötsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B, Lardeau CH, Spitzwieser M, Szabó P, Heffeter P, Lang I, Cichna-Markl M, Grasl-Kraupp B, Marian B, Grusch M, Kubicek S, Szakács G, Berger W.

Oncotarget. 2016 Aug 2;7(31):50161-50179. doi: 10.18632/oncotarget.10324.

25.

Anticancer metal drugs and immunogenic cell death.

Terenzi A, Pirker C, Keppler BK, Berger W.

J Inorg Biochem. 2016 Dec;165:71-79. doi: 10.1016/j.jinorgbio.2016.06.021. Epub 2016 Jun 16. Review.

PMID:
27350082
26.

Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells.

Kryeziu K, Pirker C, Englinger B, van Schoonhoven S, Spitzwieser M, Mohr T, Körner W, Weinmüllner R, Tav K, Grillari J, Cichna-Markl M, Berger W, Heffeter P.

Oncotarget. 2016 May 10;7(19):27379-93. doi: 10.18632/oncotarget.8415.

27.

Opposing Roles of JNK and p38 in Lymphangiogenesis in Melanoma.

Puujalka E, Heinz M, Hoesel B, Friedl P, Schweighofer B, Wenzina J, Pirker C, Schmid JA, Loewe R, Wagner EF, Berger W, Petzelbauer P.

J Invest Dermatol. 2016 May;136(5):967-977. doi: 10.1016/j.jid.2016.01.020. Epub 2016 Jan 30.

28.

EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.

Sevelda F, Mayr L, Kubista B, Lötsch D, van Schoonhoven S, Windhager R, Pirker C, Micksche M, Berger W.

J Exp Clin Cancer Res. 2015 Nov 2;34:134. doi: 10.1186/s13046-015-0251-5.

29.

Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.

Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.

J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.

PMID:
26011651
30.

Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

Garay T, Molnár E, Juhász É, László V, Barbai T, Dobos J, Schelch K, Pirker C, Grusch M, Berger W, Tímár J, Hegedűs B.

Pathol Oncol Res. 2015 Sep;21(4):957-68. doi: 10.1007/s12253-015-9916-9. Epub 2015 Mar 9.

PMID:
25749811
31.

Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance.

Miklos W, Pelivan K, Kowol CR, Pirker C, Dornetshuber-Fleiss R, Spitzwieser M, Englinger B, van Schoonhoven S, Cichna-Markl M, Koellensperger G, Keppler BK, Berger W, Heffeter P.

Cancer Lett. 2015 May 28;361(1):112-20. doi: 10.1016/j.canlet.2015.02.049. Epub 2015 Mar 5.

PMID:
25749419
32.

Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.

Spiegl-Kreinecker S, Lötsch D, Ghanim B, Pirker C, Mohr T, Laaber M, Weis S, Olschowski A, Webersinke G, Pichler J, Berger W.

Neuro Oncol. 2015 Sep;17(9):1231-40. doi: 10.1093/neuonc/nov010. Epub 2015 Feb 13.

33.

Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.

Paulitschke V, Berger W, Paulitschke P, Hofstätter E, Knapp B, Dingelmaier-Hovorka R, Födinger D, Jäger W, Szekeres T, Meshcheryakova A, Bileck A, Pirker C, Pehamberger H, Gerner C, Kunstfeld R.

Mol Cancer Ther. 2015 Mar;14(3):757-68. doi: 10.1158/1535-7163.MCT-14-0701. Epub 2015 Jan 22.

34.

The Basic Documentation for Psycho-Oncology Short Form (PO-Bado SF)--an expert rating scale for distress screening: development and psychometric properties.

Marten-Mittag B, Book K, Buchhold B, Dinkel A, Gründobler B, Henrich G, Huber B, Pirker C, Regenberg A, Schickel S, Senf B, Wünsch A, Herschbach P.

Psychooncology. 2015 Jun;24(6):653-60. doi: 10.1002/pon.3708. Epub 2014 Oct 24.

PMID:
25346529
35.

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.

Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC.

PMID:
25188816
36.

MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.

Birner P, Berghoff AS, Dinhof C, Pirker C, Capper D, Schoppmann SF, Petzelbauer P, von Deimling A, Berger W, Preusser M.

Arch Dermatol Res. 2014 Dec;306(10):873-84. doi: 10.1007/s00403-014-1490-6. Epub 2014 Jul 30.

PMID:
25073704
37.

The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis.

Izraely S, Sagi-Assif O, Klein A, Meshel T, Ben-Menachem S, Zaritsky A, Ehrlich M, Prieto VG, Bar-Eli M, Pirker C, Berger W, Nahmias C, Couraud PO, Hoon DS, Witz IP.

Int J Cancer. 2015 Mar 15;136(6):1296-307. doi: 10.1002/ijc.29090. Epub 2014 Sep 8.

38.

Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.

Gauglhofer C, Paur J, Schrottmaier WC, Wingelhofer B, Huber D, Naegelen I, Pirker C, Mohr T, Heinzle C, Holzmann K, Marian B, Schulte-Hermann R, Berger W, Krupitza G, Grusch M, Grasl-Kraupp B.

Carcinogenesis. 2014 Oct;35(10):2331-8. doi: 10.1093/carcin/bgu151. Epub 2014 Jul 16.

PMID:
25031272
39.

Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis.

Lötsch D, Steiner E, Holzmann K, Spiegl-Kreinecker S, Pirker C, Hlavaty J, Petznek H, Hegedus B, Garay T, Mohr T, Sommergruber W, Grusch M, Berger W.

Oncotarget. 2013 Nov;4(11):1904-18.

40.

New 5-Aryl-1H-imidazoles display in vitro antitumor activity against apoptosis-resistant cancer models, including melanomas, through mitochondrial targeting.

Mathieu V, Van Den Berge E, Ceusters J, Konopka T, Cops A, Bruyère C, Pirker C, Berger W, Trieu-Van T, Serteyn D, Kiss R, Robiette R.

J Med Chem. 2013 Sep 12;56(17):6626-37. doi: 10.1021/jm400287v. Epub 2013 Aug 20.

PMID:
23845202
41.

Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation.

Mathieu V, Pirker C, Schmidt WM, Spiegl-Kreinecker S, Lötsch D, Heffeter P, Hegedus B, Grusch M, Kiss R, Berger W.

Oncotarget. 2012 Apr;3(4):399-413.

42.

Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones.

Heffeter P, Pirker C, Kowol CR, Herrman G, Dornetshuber R, Miklos W, Jungwirth U, Koellensperger G, Keppler BK, Berger W.

Biochem Pharmacol. 2012 Jun 15;83(12):1623-33. doi: 10.1016/j.bcp.2012.03.004. Epub 2012 Mar 15.

43.

Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.

Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K.

Neuroendocrinology. 2012;96(3):228-37. doi: 10.1159/000337257. Epub 2012 Apr 27.

PMID:
22378048
44.

Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

Metzner T, Bedeir A, Held G, Peter-Vörösmarty B, Ghassemi S, Heinzle C, Spiegl-Kreinecker S, Marian B, Holzmann K, Grasl-Kraupp B, Pirker C, Micksche M, Berger W, Heffeter P, Grusch M.

J Invest Dermatol. 2011 Oct;131(10):2087-95. doi: 10.1038/jid.2011.177. Epub 2011 Jul 14.

45.

DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies.

Schmidt WM, Uddin MH, Dysek S, Moser-Thier K, Pirker C, Höger H, Ambros IM, Ambros PF, Berger W, Bittner RE.

PLoS Genet. 2011 Apr;7(4):e1002042. doi: 10.1371/journal.pgen.1002042. Epub 2011 Apr 14.

46.

Overexpression of Aurora-A in primary cells interferes with S-phase entry by diminishing Cyclin D1 dependent activities.

Jantscher F, Pirker C, Mayer CE, Berger W, Sutterluety H.

Mol Cancer. 2011 Mar 16;10:28. doi: 10.1186/1476-4598-10-28.

47.

A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression.

van Zijl F, Mall S, Machat G, Pirker C, Zeillinger R, Weinhaeusel A, Bilban M, Berger W, Mikulits W.

Mol Cancer Ther. 2011 May;10(5):850-60. doi: 10.1158/1535-7163.MCT-10-0917. Epub 2011 Mar 1.

48.

Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465.

Pirker C, Lötsch D, Spiegl-Kreinecker S, Jantscher F, Sutterlüty H, Micksche M, Grusch M, Berger W.

Exp Dermatol. 2010 Dec;19(12):1040-7. doi: 10.1111/j.1600-0625.2010.01182.x.

PMID:
21087322
49.

Routine psychosocial distress screening in radiotherapy: implementation and evaluation of a computerised procedure.

Dinkel A, Berg P, Pirker C, Geinitz H, Sehlen S, Emrich M, Marten-Mittag B, Henrich G, Book K, Herschbach P.

Br J Cancer. 2010 Nov 9;103(10):1489-95. doi: 10.1038/sj.bjc.6605930. Epub 2010 Oct 26.

50.

Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas.

Van Goietsenoven G, Hutton J, Becker JP, Lallemand B, Robert F, Lefranc F, Pirker C, Vandenbussche G, Van Antwerpen P, Evidente A, Berger W, Prévost M, Pelletier J, Kiss R, Kinzy TG, Kornienko A, Mathieu V.

FASEB J. 2010 Nov;24(11):4575-84. doi: 10.1096/fj.10-162263. Epub 2010 Jul 19. Erratum in: FASEB J. 2015 Sep;29(9):4080.

Supplemental Content

Loading ...
Support Center